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Background: Longer times from diagnosis to breast cancer treatment are associated with poorer prognosis. This
study examined factors associated with wait times by phase in the breast cancer treatment pathway.
Methods: There were 1760 women eligible for the study, aged 50–69 diagnosed in Ontario with invasive breast
cancer from 1995–2003. Multivariate logistic regression examined factors associated with greater than median wait
times for each phase of the treatment pathway; from diagnosis to definitive surgery; from final surgery to
radiotherapy without chemotherapy and from final surgery to chemotherapy.
Results: The median wait times were 17 days (Inter Quartile Range (IQR) = 0–31) from diagnosis to definitive
surgery, 44 days (IQR = 34–56) from final surgery to postoperative chemotherapy and 75 days (IQR = 57–97) from
final surgery to postoperative radiotherapy. Diagnosis during 2000–2003 compared to 1995–1999 was associated
with significantly longer wait times for each phase of the treatment pathway. Higher income quintile was
associated with longer wait time from diagnosis to surgery (OR = 1.47, 95% CI = 1.05-2.06) and shorter wait times
from final surgery to radiotherapy (OR = 0.60, 95% CI = 0.37-0.96). Greater stage at diagnosis was associated with
shorter wait times from diagnosis to definitive surgery (stage III vs I: OR = 0.49, 95% CI = 0.34-0.71).
Conclusions: While diagnosis during the latter part of the study period was associated with significantly longer
wait times for all phases of the treatment pathway, there were variations in the associations of stage and income
quintile with wait times by treatment phase. Continued assessment of factors associated with wait times across the
breast cancer treatment pathway is important, as they indicate areas to be targeted for quality improvement with
the ultimate goal of improving prognosis.
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The improved survival for women diagnosed with breast
cancer in Canada has been attributed to a combination
of early detection through mammography screening and
advances in evidence based treatment protocols (Canadian
Cancer Society’s Steering Committee 2011). Treatment for
breast cancer is multifaceted, and both the use of loco-
regional radiotherapy (Whelan et al. 2000) and systemic
chemotherapy (Baum 1998) has been shown to improve
breast cancer survival over use of surgery alone. However,
despite the improved survival outcomes, wait times across* Correspondence: anna.chiarelli@cancercare.on.ca
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a concern. A review examining symptomatic cancers found
that a 3–6 month delay from onset of symptoms to first
treatment was associated with overall shorter survival
among breast cancer patients (Richards et al. 1999). Re-
views examining treatment specific outcomes have found
that wait times to postoperative chemotherapy of greater
than 4 weeks are associated with shorter disease-free and
overall survival (Balduzzi et al. 2010), while wait times
longer than 8 weeks to initiation of postoperative radio-
therapy have been associated with higher local recurrence
rates, but without impact on survival (Chen et al. 2008;
Huang et al. 2003). A large Canadian study examining
women diagnosed with early stage breast cancer did find
higher local and distant recurrence rates and inferior breasts an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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more than 20 weeks following surgery, compared to those
who began within 4 to 8 weeks (Olivotto et al. 2009).
In Canada, later stage at diagnosis (Rayson et al. 2004)
and receipt of radiotherapy compared to chemotherapy
(Rayson et al. 2007) has been associated with longer wait
time to postoperative treatment in symptomatic women.
Additionally, being diagnosed greater than 70 years of
age has been associated with greater wait time from
diagnosis to first treatment (Rayson et al. 2004; Olivotto
et al. 2001). A study from Manitoba, Canada found a
periodic association between rural residence and shorter
treatment intervals, specifically among women diagnosed
in early 2001 and not in a more recent cohort, diagnosed
in 2005 (Cooke et al. 2009). The majority of these studies
included symptomatic women only.
Factors associated with variation in treatment wait
times may provide an opportunity for quality improvement
with the ultimate goal of improving prognosis for women
diagnosed with breast cancer. The present cohort included
Ontario women diagnosed between 1995 and 2003 with
screen-detected, interval, or symptomatic breast cancers.
The main objective of this study is to examine demo-
graphic, prognostic and clinical factors associated with
wait times across defined phases of the treatment path-
way; namely, from invasive breast cancer diagnosis to de-
finitive surgery, from final surgery to radiotherapy when
chemotherapy is not given, and from final surgery to
chemotherapy prior to radiotherapy.
Methods
Ethics approval for this study was granted by the Univer-
sity of Toronto Health Sciences Research Ethics Board,
the Regional Cancer Centers and Princess Margaret Hos-
pital. Methods were described thoroughly in a previous
study (Chiarelli et al. 2012). Briefly, a cohort of women
(N = 807,966) between the ages of 50–63 as of Jan 1,
1995 who registered for health care benefits through the
Ontario Health Insurance Plan (OHIP) was identified.
The cohort was linked to women in the Ontario Cancer
Registry (OCR) to ascertain the date of diagnosis of pri-
mary invasive breast cancer, of any histological type, from
Jan 1, 1995 to Dec 31, 2003. Women identified with prior
history of breast cancer (n = 15,684), unknown sex (n = 3),
who were not residents of Ontario (n = 7,633), less than
50 years of age (n = 33) or who had died before the start of
the study (n = 12,898) were excluded. Information on
mammograms performed through OHIP was obtained by
merging cohort data with OHIP files, and extracting all
physician claims for bilateral mammography during the
study period, with an algorithm to distinguish between
screening and diagnostic mammograms (Chiarelli et al.
2012). Information from women screened within the
Ontario Breast Screening Program (OBSP) was obtainedfrom data routinely collected by an integrated client man-
agement system. Since 1990, the OBSP has offered eligible
women biennial screening consisting of two view mam-
mography. A complete description of the details of OBSP
has been published (Chiarelli et al. 2006). All identified
OBSP and OHIP screens were merged to a screening his-
tory for each woman.
Of the 16,373 invasive breast cancer cases that occurred
in Ontario between 1995 and 2003, 2,615 were randomly
selected for chart abstraction. Of the 2,415 women with
available charts, 350 did not meet the eligibility criteria
(specified in Figure 1). A woman’s breast cancer was classi-
fied as screen-detected if she had a mammogram during
the study period, either through OHIP or OBSP, and her
breast cancer was diagnosed within 6 months of that
screen. Interval breast cancers were defined as cancers that
occurred within 6 to12 months of a mammogram. Symp-
tomatic breast cancers were cancers diagnosed in women
who did not have a screening mammogram during the
study period prior to diagnosis.
Phases in the treatment pathway
Wait times were examined across phases in the treatment
pathway from invasive breast cancer diagnosis to defini-
tive surgery; from final surgery to initiation of radiother-
apy without chemotherapy and from final surgery to
chemotherapy prior to radiation. Definitive surgeries in-
cluded those occurring within 4 months of a tissue diag-
nosis. A definitive surgery was defined for each woman
as the first procedure after diagnosis, coded as partial
mastectomy (with a prior FNA or core biopsy), mastec-
tomy, axillary lymph node dissection (ALND) or Sentinel
Lymph Node Biopsy (SLNB). Wait time to postoperative
adjuvant treatment was calculated from the date of final
surgery following diagnosis (which included incisional/
excisional biopsy, mastectomy, ALND, SLNB and re-
excisions) to the date of first adjuvant chemotherapy or
breast radiotherapy. Adjuvant treatment included those
occurring within 1 year of diagnosis.
Definition of covariates
Information on tumour characteristics was abstracted
from pathology and surgical reports included in the med-
ical charts (Chiarelli et al. 2012). The TNM classification
scheme was used for staging of breast cancer (American
Joint Committee on Cancer 2002). Tumour size was de-
fined as the largest diameter of the invasive carcinoma.
Among women who had axillary assessment with either
sentinel lymph node biopsy or axillary node dissection,
lymph node status was defined as positive by TNM cri-
teria. Biopsies included those conducted within a day of
the diagnosis date and were either percutaneous, (FNA
and core biopsies) or surgical (excisional biopsy or partial
mastectomy). OCR data was used to obtain age and date
N=2,615 Charts randomly selected
N=2,415 Charts available
N=2,065 Met Eligibility Criteria
Diagnosed with primary invasive breast 
cancer between Jan 1 1995 to Dec 31 2003
Aged 50-69 years at diagnosis
Received treatment in Ontario
Diagnosed within 24 months of screen
Overall Sample N=1,760




Diagnostic interval <0 or 
>365 days (n=21)
Invalid first biopsy or 
imaging date/type (n=22)
Stage 4 or un-staged 
cancers (n=212)
N=1,760 women with 
definitive surgery
N=564 women with 
chemotherapy
N=1,381 women with 
radiotherapy
Phases of the Treatment Pathway
Phase 1: Diagnosis to 
definitive surgery (n=1,675)
Phase 2: Final Surgery to 
chemotherapy (n=498)

















Had chemotherapy or 
radiotherapy before 
surgery (n=14)
Figure 1 Flow chart of study population leading to final cohorts for treatment analysis.
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center was classified as the cancer center the woman first
attended, and grouped according to geographic region.
South Central region included Toronto and Hamilton,
South Eastern region included Ottawa and Kingston,
South Western region included London and Windsor and
Northern region included Sudbury and Thunder Bay.
Postal codes from either residence at first screen (interval
and screen-detected cases) or the start of the study period,
January 1, 1995 (symptomatic cases) were linked to the
2001 Canadian census to obtain neighborhood income
quintile (Chiarelli et al. 2012).
Statistical analysis
Clinical characteristics and treatments received were ex-
amined overall and by detection method. For each phase
in the treatment pathway, the distribution of wait times
was quantified by the median and interquartile range(IQR). As treatment wait times were skewed, with more
women experiencing relatively shorter compared to lon-
ger wait times, comparisons of wait times between detec-
tion groups were performed using the non-parametric
Wilcoxon Rank sum test. Logistic regression analysis ex-
amined associations between factors and treatment wait
times, dichotomized as greater or less than the observed
median. Adjusted odds ratios (OR) and 95% confidence
intervals (95%CI) were estimated to quantify associations,
and statistical significance was evaluated using 2-sided
p-values at the 5% testing level. All statistical analyses were
performed using SAS 9.2 (SAS Institute Inc 2008).
Results
Of 2065 eligible women diagnosed with invasive breast
cancer, 1760 had valid biopsy types and dates, and were
diagnosed at stages I to III (Figure 1). There were 1675
women included in the diagnosis to definitive surgery
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to chemotherapy analysis and 812 women in the sur-
gery to radiotherapy analysis, including women receiv-
ing endocrine therapy (see Figure 1 for exclusions). There
were a greater number of interval cancers (p = 0.02), and
fewer symptomatic cancers (p = 0.01), compared to screen-
detected cancers diagnosed in the latter time period
(Table 1). Both symptomatic and interval cancers were
more likely to be diagnosed at stage III vs. I (p < 0.001),
and be treated with chemotherapy (p < 0.01) compared to
screen-detected cancers. Symptomatic cancers were also
significantly less likely to have radiotherapy compared to
screen-detected cancers, although a greater proportion
also had mastectomy.
Overall, the most common treatments were surgery
with radiotherapy (47.6%) and a combination of surgery,Table 1 Distribution of clinical characteristics and treatment r
screen-detected, interval and symptomatic breast cancers (n
Overall Scree
N = 1,760 N = 1
Characteristics N (%) N (%)
Age Category
50-59 680 (38.6) 415 (3
60-69 1080 (61.4) 681(6
Diagnosis Year*
1995-1999 974 (55.3) 602 (5
2000-2003 786 (44.7) 494 (4
Chemotherapy†
No chemotherapy 1098 (62.4) 728 (6
Chemotherapy 662 (37.6) 368(3
Radiotherapya‡
No Radiotherapy 370 (21.2) 218 (1
Radiotherapy 1377 (78.8) 873 (7
Definite Surgerybδ
Incisional/excisional 112 (6.6) 79 (7.5
Partial Mastectomy 1071 (63.4) 688 (6
Total Mastectomy 101 (6.0) 55 (5.2
Modified/Radical Mast. 328 (19.4) 185 (1
ALND/SLNB 77 (4.6) 54 (5.1
TNM Stage**
1 925 (52.6) 662 (6
2 603 (34.3) 332 (3
3 232 (13.2) 102 (9
aUnknown radiotherapy n = 13.
bunknown surgery type n = 27; invalid surgery type n = 44.
*difference for interval (p = 0.02) and symptomatic (p = 0.01) compared to screen-d
†difference for interval (p = 0.003) and symptomatic (p < 0.001) compared to screen
‡difference for symptomatic compared to screen-detected (p = 0.01).
δdifference for symptomatic compared to screen-detected (p = 0.003).
**difference for interval (p < 0.001) and symptomatic (p < 0.001) compared to screechemotherapy and radiotherapy (31.4%) (Table 2). The per-
centage of women treated with surgery and radiotherapy
was 52%, 45% and 36% for women with screen-detected,
interval and symptomatic cancers, respectively. An oppos-
ite pattern was observed for treatment with surgery,
chemotherapy and radiotherapy where 29%, 36% and 37%
of women were screen-detected, interval and symptomatic,
respectively (Table 2). The median wait time from diagno-
sis to definitive surgery was 17 days (IQR = 0-31 days), with
10% of women waiting 49 days or more. The median wait
times from surgery to chemotherapy was 44 days (IQR =
34-56 days), with 10% of women waiting longer than
70 days. Among women who did not receive chemother-
apy, the median wait time to radiotherapy was 75 days
(IQR = 57-97 days), with 10% of women waiting 118 days
or longer. There were no significant differences in medianeceived overall, and among women diagnosed with
= 1,760)
n-detected Interval Symptomatic
096 N = 309 N = 355
N (%) N (%)
7.9) 124 (40.1) 141 (39.7)
2.1) 185 (59.9) 214 (60.3)
4.9) 147 (47.6) 225 (63.4)
5.1) 162 (52.4) 130 (36.6)
6.4) 177 (57.3) 193 (62.8)
3.6) 132 (42.7) 162 (37.2)
9.9) 58 (18.8) 94 (26.5)
9.7) 246 (79.6) 258 (72.7)
) 14 (4.7) 19 (5.8)
4.8) 185 (62.0) 198 (60.0)
) 24 (8.1) 22 (6.7)
7.4) 59 (19.8) 84 (25.5)
) 16 (5.4) 7 (2.1)
0.4) 161 (52.1) 102 (28.7)
0.3) 97 (31.4) 174 (49.0)




Table 2 Description of wait times to definitive surgery, radiotherapy and chemotherapy overall, and among women
diagnosed with screened, interval and symptomatic breast cancers
Overall Screen-detected Interval Symptomatic
N = 1760 N = 1096 N = 309 N = 355
N (%) N (%) N (%) N (%)
Treatments Receiveda
Surgery + Chemotherapy 110 (6.3) 60 (5.5) 20 (6.5) 30 (8.5)
Surgery + Radiotherapy 838 (47.6) 570 (52.0) 139 (45.0) 129 (36.2)
Surgery + Chemotherapy + Radiotherapy 552 (31.4) 308 (29.0) 112 (36.2) 132 (37.2)
Surgery Only 260 (14.8) 158 (14.4) 38 (12.3) 64 (18.0)
Diagnosis to Definitive Surgeryb
Number In analysis N = 1675 N = 1056 N = 293 N = 326
Median Wait Time to Definitive Surgery 17 days 18 days 20 days 15 days
IQR 0-31 days 0-31 days 0-33 days 0-30 days
90th Percentile > 49 days 49 days 51 days 49 days
Final Surgery to Chemotherapyc
Number in analysis N = 498 N = 290 N = 98 N = 110
Median Wait Time to Chemotherapy 44 days 43 days 43 days 46 days
IQR 34-56 days 33-56 days 35-58 days 34-54 days
90th Percentile > 70 days 71 days 71 days 66 days
Final Surgery to Radiotherapyd
Number In analysis N = 812 N = 556 n = 132 N = 124
Median Wait Time to Radiotherapy 75 days 75 days 73.5 days 78 days
IQR 57-97 days 57-96 days 59-97 days 59-100 days
90th Percentile > 118 days 118 days 112 days 138 days
aPearson chi-squared test; difference in treatments received for interval (p = 0.031) and symptomatic (p < 0.001) compared to screen-detected.
bWilcoxon rank sum test; difference in wait times for interval (p = 0.137) and symptomatic (p = 0.191) compared to screen-detected.
cWilcoxon rank sum test; difference in wait times for interval (p = 0.504) and symptomatic (p = 0.573) compared to screen-detected.
dWilcoxon rank sum test; difference in wait times for interval (p = 911) and symptomatic (p = 0.170) compared to screen-detected.
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tween screen-detected, interval or symptomatic cancers.
After controlling for demographic and prognostic fac-
tors, diagnosis during 2000–2003 compared to 1995–
1999 was associated with significantly greater wait time
from diagnosis to definitive surgery (OR = 2.29, 95%
CI = 1.85-2.86), from final surgery to chemotherapy (OR =
1.62, 95%CI = 1.10-2.41) and from final surgery to radio-
therapy (OR = 2.55, 95%CI 1.86-3.52) (Table 3). Compared
to those who had treatment in the South Central region,
having treatment in the South Eastern region of Ontario
was associated with longer wait times to definitive sur-
gery (OR = 1.96, 95%CI = 1.51-2.56) and to chemotherapy
(OR = 1.76, 95% CI = 1.12-2.78), but shorter wait time to
radiotherapy (OR = 0.40, 95%CI = 0.27-0.58). Having treat-
ment in the South Western region was associated only with
an increased wait time to definitive surgery (OR = 1.36, 95%
CI = 1.03-1.81), while having treatment in the Northern re-
gion was associated with shorter wait times to definitive
surgery (OR = 0.57, 95%CI = 0.41-0.81) and to radiotherapy
(OR = 0.33, 95%CI = 0.20-0.55). Higher income quintile wasassociated with greater wait times from diagnosis to defini-
tive surgery (OR = 1.49, 95%CI = 1.05-2.09 for Q2 vs. Q1;
OR = 1.47, 95%CI = 1.05-2.06 for Q4 vs. Q1) and shorter
wait times from surgery to radiotherapy (OR = 0.60, 95%
CI = 0.37-0.96 for Q5 vs. Q1). Women diagnosed with
stage III compared to stage I breast cancers were less
likely to experience greater wait time to definitive surgery
(OR = 0.49, 95%CI = 0.34-0.71) while no differences were
observed for the wait times to other treatments.
Discussion
In this cohort of Ontario women, over 75% had wait
times within current clinical practice guidelines from
diagnosis to definitive surgery or final surgery to postop-
erative chemotherapy and about 50% had acceptable wait
times to postoperative radiotherapy without chemother-
apy. Regardless of phase in the treatment pathway, wait
times did not differ significantly by detection method.
Factors associated with wait times differed by phase of
the treatment pathway, except for time period where wait
times were consistently significantly longer for women
Table 3 Adjusted odds ratios (OR) and 95%CI describing factors associated with wait times from diagnosis to definitive surgery (n = 1,675), and from final
surgery to postoperative chemotherapy (n = 498) or postoperative radiotherapy (n = 812)
Diagnosis→Definitive surgerya (n = 1,675) Surgery to chemotherapyb (n = 498) Surgery to radiotherapyc ( n = 812)
Wait time
≤17 days n (%)
Wait time




≤44 days n (%)
Wait time




< 75 days n (%)
Wait time




Screened 527 (62.6) 529 (63.5) 1.00 reference 155 (60.3) 135 (56.0) 1.00 reference 281 (68.9) 275 (68.1) 1.00 reference
Interval 133 (15.8) 160 (19.2) 1.14 (0.86-1.51) 50 (19.5) 48 (19.9) 1.01 (0.62-1.64) 68 (16.7) 64 (15.8) 0.92 (0.60-1.38)
Symptomatic 182 (21.6) 144 (17.3) 0.93 (0.71-1.24) 52 (20.2) 58 (24.1) 1.35 (0.84-2.19) 59 (14.5) 65 (16.1) 1.09 (0.70-1.68)
Age at Diagnosis
50-59 364 (43.2) 285 (34.2) 1.00 reference 129 (50.2) 97 (40.3) 1.00 reference 155 (38.0) 125 (30.9) 1.00 reference
60-69 478 (56.8) 548 (65.8) 0.97 (0.67-1.40) 128 (49.8) 144 (59.8) 1.45 (0.98 -2.14) 253 (62.0) 279 (69.1) 1.12 (0.82-1.55)
Diagnosis Year
1995-1999 555 (65.9) 374 (44.9) 1.00 reference 141 (54.9) 100 (41.5) 1.00 reference 281 (68.9) 197 (48.8) 1.00 reference
2000-2003 287 (34.1) 459 (55.1) 2.29 (1.85-2.86)* 116 (45.1) 141 (58.5) 1.62 (1.10-2.41)‡ 127 (31.1) 207 (51.2) 2.55 (1.86-3.52)*
Income Quintile
Q1 (poorest) 167 (20.0) 130 (15.7) 1.00 reference 45 (17.7) 44 (18.5) 1.00 reference 63 (15.6) 72 (18.0) 1.00 reference
Q2 140 (16.8) 165 (20.0) 1.49 (1.05-2.09)‡ 40 (15.7) 48 (20.2) 1.26 (0.68-2.34) 78 (19.3) 65 (16.2) 0.68(0.41-1.12)
Q3 162 (19.4) 155 (18.8) 1.21 (0.86-1.71) 52 (20.4) 42 (17.7) 0.78 (0.42-1.45) 68 (16.8) 85 (21.2) 0.90 (0.54-1.48)
Q4 154 (18.4) 178 (21.6) 1.47 (1.05-2.06)‡ 54 (21.2) 48 (20.2) 0.96 (0.53-1.75) 77 (19.0) 87 (21.7) 0.84 (0.51-1.38)
Q5 (richest) 212 (25.4) 198 (24.0) 1.16 (0.84-1.61) 64 (25.1) 56 (23.5) 0.84 (0.47-1.50) 119 (29.4) 92 (22.9) 0.60 (0.37-0.96)†
Treatment Centre
Region
South Central 423 (50.2) 332 (39.9) 1.00 reference 123 (47.9) 99 (41.1) 1.00 reference 156 (38.2) 199 (49.3) 1.00 reference
South Eastern 155 (18.4) 253 (30.4) 1.96 (1.51-2.56)* 60 (23.4) 76 (31.5) 1.76 (1.12-2.78)∂ 129 (31.6) 68 (16.8) 0.40 (0.27-0.58)*
South Western 137 (16.3) 173 (20.8) 1.36 (1.03-1.81)† 31 (12.1) 41 (17.0) 1.67 (0.94-2.94) 58 (14.2) 102 (25.3) 1.24 (0.83-1.87)
Northern 127 (15.1) 75 (9.0) 0.57 (0.41-0.81)* 43 (16.7) 25 (10.4) 0.59 (0.32-1.09) 65 (15.9) 35 (8.7) 0.33 (0.20-0.55)*
TNM Stage
1 432 (51.3) 460 (55.2) 1.00 reference 57 (22.2) 46 (19.1) 1.00 reference 323 (79.2) 312 (77.2) 1.00 reference
2 296 (35.2) 284 (34.1) 0.86 (0.68-1.08) 138 (53.7) 132 (54.8) 1.15 (0.69-1.88) 80 (19.6) 83 (20.5) 1.18 (0.80-1.74)
3 114 (13.5) 89 (10.7) 0.49 (0.34-0.71)* 62 (24.1) 63 (26.1) 1.19 (0.66-2.13) 5 (1.2) 9 (2.2) 2.83 (0.74-10.8)
aAdjusted for: detection method, age category, diagnosis year, treatment centre, income quintile, stage and definitive surgery type.
bAdjusted for: detection method age category, diagnosis year, treatment centre, income quintile, stage and last surgery type and hormone status.
cAdjusted for: detection method, age category, diagnosis year, treatment centre, income quintile, stage and last surgery type.
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for all phases. Higher stage at diagnosis was significantly
associated with shorter wait times to definitive surgery, but
not with wait times to any post-surgical treatment. Higher
income quintile was also significantly associated with lon-
ger wait time to surgery, and shorter times to radiotherapy.
In addition, there were substantial regional differences in
wait times during this period.
The most common breast cancer treatment for women
with screen-detected or interval cancer was breast surgery
with radiotherapy. This is expected as breast irradiation
following breast conserving surgery was a standard treat-
ment in Canada during the study period (Whelan et al.
2003). Compared to screen-detected cancers, a greater
proportion of symptomatic cancers received mastectomy,
which may explain the significantly lower odds of post-
surgical radiotherapy in this group. Whether a woman had
screen-detected, compared to interval or symptomatic
breast cancer, was not a major predictor of wait times from
diagnosis to definitive surgery, or to post-surgical chemo-
therapy or radiotherapy. This finding suggests that once a
woman is diagnosed with cancer, the detection method
does not substantially impact wait times to treatments.
The Canadian Steering Committee on Clinical Practice
Guidelines for the Care and Treatment of Breast Cancer
currently recommends that local breast irradiation not
accompanied by chemotherapy should commence within
12 weeks after surgery (Whelan et al. 2003) and that ad-
juvant chemotherapy begin as soon as possible following
surgical healing (Cancer Care Ontario 2010). In our co-
hort, the median times to postoperative chemotherapy
(6.3 weeks) and radiotherapy (10 weeks), were within these
clinically acceptable time frames. However, the upper 10%
of women experienced intervals of greater than 10.0 weeks
for chemotherapy. It has been shown that relapse free
survival and overall survival are impacted when a women
begins chemotherapy more than 10 to 12 weeks following
surgery (Shannon et al. 2003; Baum 1998; Balduzzi
et al. 2010). Among women who received postoperative
radiotherapy, 10% had treatment intervals of greater than
17 weeks. A recent population based Canadian study
examining impact of treatment times among women di-
agnosed with early stage breast cancer, found increased
recurrence rates and inferior breast cancer specific sur-
vival for women who began radiotherapy greater than
20 weeks following surgery, compared to within 4–8 weeks
(Olivotto et al. 2009). We found that 90% of women re-
ceived surgery within 7 weeks of their diagnosis, with me-
dian time to surgery of 2.4 weeks, which was lower than
12 weeks, the recommendation during the study period
(Canadian Breast Cancer Network 2008).
Being diagnosed with breast cancer in the latter part
of the study, 2000 to 2003, compared to the earlier, 1995
to 1999, was associated with an increased wait timefrom diagnosis to definitive surgery and also with wait
time from surgery to both chemotherapy and radiotherapy.
Similarly a study conducted in Nova Scotia, Canada during
a similar time period also found that time to first adjuvant
therapy (chemotherapy or radiotherapy), following sur-
gery was substantially longer for the more recent cohort
(2003/2004) compared to the more distant one(1999/2000)
(Rayson et al. 2007). Longer wait times for radiotherapy in
the later cohort may be explained by a shortage of radi-
ation therapists, medical physicists and radiation oncolo-
gists in the late 1990’s, such that some patients had to be
seen out of province for treatment (D’Souza et al. 2001;
Randal 2000). The explanations for lengthening wait times
for definitive surgery and chemotherapy are less readily ap-
parent, but may include increasing cancer incidence with
disproportionately smaller increases in resources for cancer
surgery and increased use of chemotherapy for node nega-
tive breast cancer in the later time period.
Regional differences in wait times were observed in
this cohort. Compared to having treatment in the South-
Central region of the province, having treatment in the
North was associated with shorter wait times to radio-
therapy and having treatment in the South East region
was associated with longer wait times to definitive sur-
gery, and chemotherapy, but shorter wait time to radio-
therapy. Similar regional variation in radiotherapy wait
times have been observed in Ontario among women not
receiving chemotherapy (Olivotto et al. 2009). This may
also be explained by the shortage of radiation therapists,
physicists and radiation oncologists in different regions
(D’Souza et al. 2001; Randal 2000). A variety of systemic,
organizational and procedural differences, including cap-
acity to provide therapy, may be concurrently contribut-
ing to the observed variation (Benk et al. 2006). Regional
variation in wait times continue to be monitored as an
important indicator of the cancer delivery system across
the province (Cancer Care Ontario 2010).
Contrary to other literature, we did not find age at
diagnosis to be associated with wait times for any of the
treatment phases. While other studies included women
over the age of 70, ours included women up to age 69 only,
which may explain some of the discrepancies (Rayson et al.
2004; Caplan et al. 2000). We found that increasing income
quintile was associated with shorter wait time to radio-
therapy, but with longer time to definitive surgery. Our
study is not directly comparable to other studies which
have assessed individual income as a predictor of wait
time to treatment, as we have used an area level in-
come measure categorized into quintiles. A study out of
Montreal, Canada, which examined personal income as a
predictor of wait times among women diagnosed with early
stage breast cancer did not find any association between
median income and delay in post-surgical radiotherapy
(classified as more than 7 weeks without chemotherapy,
Plotogea et al. SpringerPlus 2013, 2:388 Page 8 of 9
http://www.springerplus.com/content/2/1/388and more than 24 weeks with chemotherapy) (Benk et al.
1998). Wait time from diagnosis to definitive surgery was
substantially shorter for women diagnosed with stage III
compared to stage I cancers. This observation is consistent
with the expedition of diagnosis and treatment of more se-
vere cases. Expedition of treatment for cancers at higher
stages has been seen in other Canadian provinces (Caplan
et al. 2000), as has expedition to diagnosis of more suspect
cases (Olivotto et al. 2001; Arndt et al. 2003). Alternatively,
women diagnosed at a higher stage were less likely to re-
ceive breast conserving surgery; the decision to conserve
the breast may necessitate other investigations post diagno-
sis but before surgery to accurately define the volume of
breast tissue to be removed. Such investigations often con-
tribute to longer wait times from diagnosis to surgery. Not-
ably, stage did not affect post-surgical adjuvant treatment
wait times in our study.
Strengths of this study include the large cohort of
breast cancer cases identified through the OCR. Evalu-
ation of the OCR suggests a high level of completeness
and accuracy for breast cancer ascertainment (Holowaty
et al. 1995). Furthermore, through the chart abstraction,
we were able to obtain detailed information on type and
dates of treatment procedure and staging of the diag-
nosed breast cancer cases. Several limitations should be
addressed. Currently, Ontario measures wait times from
ready to treat dates, which we did not collect, thus our
findings are not directly comparable to current standards.
Additionally, although wait times are sometimes seen as
a reflection of the cancer system efficiency, these wait
time intervals may be influenced by a variety of patient
and system level factors, such as delays in seeking treat-
ment, scheduling appointments or availability of specialists,
which are not captured by our data. Also, it is import-
ant to note that this is a historic cohort, and continued
assessment is required to evaluate factors associated with
wait times as breast cancer treatment protocols and prac-
tices evolve.
In our study, over 75% of Ontario women diagnosed
with breast cancer from 1995 to 2003 had wait times
from diagnosis to definitive surgery or final surgery to
postoperative chemotherapy within current clinical prac-
tice guidelines; whereas, about half of the women had
acceptable wait times from final surgery to postoperative
radiotherapy without chemotherapy. Breast cancer de-
tection method did not substantially impact wait times
by treatment pathway. While stage of cancer was a de-
terminant of wait times to definitive surgery, it was not
associated with time to post-surgical chemotherapy or
radiotherapy. Other factors associated with longer wait
times that varied by phase of the treatment pathway
included income quintile and region of cancer treatment
centre. More recent time period of diagnosis (2000–2003)
was associated with longer wait times for all phases of thetreatment pathway. Continued assessment of factors asso-
ciated with wait times from diagnosis to surgery and to
post-surgical treatment is important, as they indicate areas
to be targeted for quality improvement with the ultimate
goal of improving prognosis for women diagnosed with
breast cancer.
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